Thu . 20 Jul 2020
TR | RU | UK | KK | BE |


chikungunya virus, chikungunya
Chikungunya is an infection caused by the chikungunya virus CHIKV3 Symptoms include fever and joint pain2 These typically occur two to twelve days after exposure3 Other symptoms may include headache, muscle pain, joint swelling, and a rash Most people are better within a week; however, occasionally the joint pain may last for months2 The risk of death is around 1 in 1,0004 The very young, old, and those with other health problems are at risk of more severe disease2

The virus is spread between people by two types of mosquitos: Aedes albopictus and Aedes aegypti3 They mainly bite during the day5 The virus may circulate within a number of animals including birds and rodents Diagnosis is by either testing the blood for the virus's RNA or antibodies to the virus The symptoms can be mistaken for those of dengue fever and Zika fever3 After a single infection it is believed most people become immune22

The best means of prevention is overall mosquito control and the avoidance of bites in areas where the disease is common4 This may be partly achieved by decreasing mosquitoes' access to water and with the use of insect repellent and mosquito nets There is no vaccine and no specific treatment as of 20163 Recommendations include rest, fluids, and medications to help with fever and joint pain32

While the disease typically occurs in Africa and Asia, outbreaks have been reported in Europe and the Americas since the 2000s In 2014 more than a million suspected cases occurred3 In 2014 it was occurring in Florida in the continental United States but as of 2016 there was no further locally acquired cases67 The disease was first identified in 1952 in Tanzania3 The term is from the Kimakonde language and means "to become contorted"3


  • 1 Signs and symptoms
    • 11 Chronic disease
  • 2 Cause
    • 21 Virology
    • 22 Transmission
  • 3 Mechanism
    • 31 Viral replication
  • 4 Diagnosis
  • 5 Prevention
    • 51 Vaccine
  • 6 Treatment
    • 61 Chronic arthritis
  • 7 Prognosis
  • 8 Epidemiology
  • 9 History
  • 10 Biological weapon
  • 11 Research
  • 12 References
  • 13 External links

Signs and symptomsedit

The incubation period of the chikungunya virus ranges from one to twelve days, and is most typically three to seven8 The disease may be asymptomatic, but generally is not, as 72% to 97% of those infected will develop symptoms8 Characteristic symptoms include sudden onset with high fever, joint pain, and rash Other symptoms may occur, including headache, fatigue, digestive complaints, and conjunctivitis9

Information gained during recent epidemics suggests that chikungunya fever may result in a chronic phase as well as the phase of acute illness10 Within the acute phase, two stages have been identified: a viral stage during the first five to seven days, during which viremia occurs,11 followed by a convalescent stage lasting approximately ten days, during which symptoms improve and the virus cannot be detected in the blood8 Typically, the disease begins with a sudden high fever that lasts from a few days to a week, and sometimes up to ten days The fever is usually above 39 °C 102 °F and sometimes reaching 40 °C 104 °F and may be biphasic—lasting several days, breaking, and then returning Fever occurs with the onset of viremia, and the level of virus in the blood correlates with the intensity of symptoms in the acute phase11 When IgM, an antibody that is a response to the initial exposure to an antigen, appears in the blood, viremia begins to diminish However, headache, insomnia and an extreme degree of exhaustion remain, usually about five to seven days12

Following the fever, strong joint pain or stiffness occurs; it usually lasts weeks or months, but may last for years The joint pain can be debilitating, often resulting in near immobility of the affected joints13 Joint pain is reported in 87–98% of cases, and nearly always occurs in more than one joint, though joint swelling is uncommon8 Typically the affected joints are located in both arms and legs, and are affected symmetrically Joints are more likely to be affected if they have previously been damaged by disorders such as arthritis10 Pain most commonly occurs in peripheral joints, such as the wrists, ankles, and joints of the hands and feet as well as some of the larger joints, typically the shoulders, elbows and knees810 Pain may also occur in the muscles or ligaments

Rash occurs in 40-50% of cases, generally as a maculopapular rash occurring two to five days after onset of symptoms8 Digestive symptoms, including abdominal pain, nausea, vomiting or diarrhea, may also occur8914 In more than half of cases, normal activity is limited by significant fatigue and pain8 Infrequently, inflammation of the eyes may occur in the form of iridocyclitis, or uveitis, and retinal lesions may occur15

Temporary damage to the liver may occur16

Rarely, neurological disorders have been reported in association with chikungunya virus, including Guillain–Barré syndrome, palsies, meningoencephalitis, flaccid paralysis and neuropathy9 In contrast to dengue fever, Chikungunya fever very rarely causes hemorrhagic complications Symptoms of bleeding should lead to consideration of alternative diagnoses or co-infection with dengue fever or coexisting congestive hepatopathy11

Chronic diseaseedit

Observations during recent epidemics have suggested chikungunya may cause long-term symptoms following acute infection171819 This condition has been termed chronic chikungunya virus-induced arthralgia4 Long-term symptoms are not an entirely new observation; long-term arthritis was observed following an outbreak in 197920 Common predictors of prolonged symptoms are advanced age and prior rheumatological disease21222324

During the La Reunion outbreak in 2006, more than 50% of subjects over the age of 45 reported long-term musculoskeletal pain22 with up to 60% of people reporting prolonged painful joints three years following initial infection21 A study of imported cases in France reported that 59% of people still suffered from arthralgia two years after acute infection25 Following a local epidemic of chikungunya in Italy, 66% of people reported muscle pains, joint pains, or asthenia at one year after acute infection23

Currently, the cause of these chronic symptoms is not fully known Markers of autoimmune or rheumatoid disease have not been found in people reporting chronic symptoms2126 However, some evidence from humans and animal models suggests chikungunya may be able to establish chronic infections within the host Viral antigen was detected in a muscle biopsy of a person suffering a recurrent episode of disease three months after initial onset27 Additionally, viral antigen and viral RNA were found in macrophages in the synovial joint of a person experiencing a relapse of musculoskeletal disease 18 months after initial infection28 Several animal models have also suggested chikungunya virus may establish persistent infections In a mouse model, viral RNA was detected specifically in joint-associated tissue for at least 16 weeks after inoculation, and was associated with chronic synovitis29 Similarly, another study reported detection of a viral reporter gene in joint tissue of mice for weeks after inoculation30 In a nonhuman primate model, chikungunya virus was found to persist in the spleen for at least six weeks31



Chikungunya virus
Virus classification
Group: Group IV +ssRNA
Order: Unassigned
Family: Togaviridae
Genus: Alphavirus
Species: Chikungunya virus

Chikungunya virus CHIKV, is a member of the alphavirus genus, and Togaviridae family It was first isolated in 1953 in Tanzania and is an RNA virus with a positive-sense single-stranded genome of about 116kb33 It is a member of the Semliki Forest virus complex and is closely related to Ross River virus, O'nyong'nyong virus, and Semliki Forest virus34 Because it is transmitted by arthropods, namely mosquitoes, it can also be referred to as an arbovirus arthropod-borne virus In the United States, it is classified as a category C priority pathogen,35 and work requires biosafety level III precautions36


Chikungunya is generally transmitted from mosquitoes to humans Less common modes of transmission include vertical transmission, which is transmission from mother to child during pregnancy or at birth Transmission via infected blood products and through organ donation is also theoretically possible during times of outbreak, though no cases have yet been documented10

Chikungunya is related to mosquitoes, their environments, and human behavior The adaptation of mosquitoes to the changing climate of North Africa around 5,000 years ago made them seek out environments where humans stored water Human habitation and the mosquitoes’ environments were then very closely connected During periods of epidemics humans are the reservoir of the virus Because high amounts of virus are present in the blood in the beginning of acute infection, the virus can be spread from a viremic human to a mosquito, and back to a human37 During other times, monkeys, birds and other vertebrates have served as reservoirs38 Three genotypes of this virus have been described, each with a distinct genotype and antigenic character: West African, East/Central/South African, and Asian genotypes39 The Asian lineage originated in 1952 and has subsequently split into two lineages - India Indian Ocean Lineage and South East Asian clades This virus was first reported in the Americas in 2014 Phylogenetic investigations have shown that there are two strains in Brazil - the Asian and East/Central/South African types - and that the Asian strain arrived in the Caribbean most likely from Oceania in about March 201340 The rate of molecular evolution was estimated to have a mean rate of 5 × 10−4 substitutions per site per year 95% higher probability density 29-79 × 10−4 typical of RNA viruses

Chikungunya is spread through bites from Aedes mosquitoes, and the species A aegypti was identified as the most common vector, though the virus has recently been associated with many other species, including A albopictus10 Research by the Pasteur Institute in Paris has suggested chikungunya virus strains in the 2005-2006 Reunion Island outbreak incurred a mutation that facilitated transmission by the Asian tiger mosquito A albopictus41 Other species potentially able to transmit the chikungunya virus include Ae furcifer-taylori, Ae africanus, and Ae luteocephalus10


The chikungunya virus is passed to humans when a bite from an infected mosquito breaks the skin and introduces the virus into the body The pathogenesis of chikungunya infection in humans is still poorly understood, despite recent outbreaks It appears that in vitro, chikungunya virus is able to replicate in human epithelial and endothelial cells, primary fibroblasts, and monocyte-derived macrophages Viral replication is highly cytopathic, but susceptible to type-I and -II interferon42 In vivo, in studies using living cells, chikungunya virus appears to replicate in fibroblasts, skeletal muscle progenitor cells, and myofibers274344

The type-1 interferon response seems to play an important role in the host's response to chikungunya infection Upon infection with chikungunya, the host's fibroblasts produce type-1 alpha and beta interferon IFN-α and IFN-β45 In mouse studies, deficiencies in INF-1 in mice exposed to the virus cause increased morbidity and mortality454647 The chikungunya-specific upstream components of the type-1 interferon pathway involved in the host's response to chikungunya infection are still unknown48 Nonetheless, mouse studies suggest that IPS-1 is an important factor,48 and that IRF3 and IRF7 are important in an age-dependent manner4950 Mouse studies also suggest that chikungunya evades host defenses and counters the type-I interferon response by producing NS2, a nonstructural protein that degrades RBP1 and turns off the host cell's ability to transcribe DNA51 NS2 interferes with the JAK-STAT signaling pathway and prevents STAT from becoming phosphorylated52

In the acute phase of chikungunya, the virus is typically present in the areas where symptoms present, specifically skeletal muscles, and joints In the chronic phase, it is suggested that viral persistence the inability of the body to entirely rid itself of the virus, lack of clearance of the antigen, or both, contribute to joint pain The inflammation response during both the acute and chronic phase of the disease results in part from interactions between the virus and monocytes and macrophages11 Chikungunya virus disease in humans is associated with elevated serum levels of specific cytokines and chemokines High levels of specific cytokines have been linked to more severe acute disease: interleukin-6 IL-6, IL-1β, RANTES, monocyte chemoattractant protein 1 MCP-1, monokine induced by gamma interferon MIG, and interferon gamma-induced protein 10 IP-10 Cytokines may also contribute to chronic chikungunya virus disease, as persistent joint pain has been associated with elevated levels of IL-6 and granulocyte-macrophage colony-stimulating factor GM-CSF37 In those with chronic symptoms, a mild elevation of C-reactive protein CRP has been observed, suggesting ongoing chronic inflammation However, there is little evidence linking chronic chikungunya virus disease and the development of autoimmunity

Viral replicationedit

Transmission electron micrograph of Chikungunya virus particles

The virus consists of four nonstructural proteins and three structural proteins11 The structural proteins are the capsid and two envelope glycoproteins: E1 and E2, which form heterodimeric spikes on the viron surface E2 binds to cellular receptors in order to enter the host cell through receptor-mediated endocytosis E1 contains a fusion peptide which, when exposed to the acidity of the endosome in eukaryotic cells, dissociates from E2 and initiates membrane fusion that allows the release of nucleocapsids into the host cytoplasm, promoting infection53 The mature virion contains 240 heterodimeric spikes of E2/E1, which after release, bud on the surface of the infected cell, where they are released by exocytosis to infect other cells33


Chikungunya is diagnosed on the basis of clinical, epidemiological, and laboratory criteria Clinically, acute onset of high fever and severe joint pain would lead to suspicion of chikungunya Epidemiological criteria consist of whether the individual has traveled to or spent time in an area in which chikungunya is present within the last twelve days ie the potential incubation period Laboratory criteria include a decreased lymphocyte count consistent with viremia However a definitive laboratory diagnosis can be accomplished through viral isolation, RT-PCR, or serological diagnosis54

The differential diagnosis may include infection with other mosquito-borne viruses, such as dengue or malaria, and infection with influenza Chronic recurrent polyarthralgia occurs in at least 20% of chikungunya patients one year after infection, whereas such symptoms are uncommon in dengue55

Virus isolation provides the most definitive diagnosis, but takes one to two weeks for completion and must be carried out in biosafety level III laboratories56 The technique involves exposing specific cell lines to samples from whole blood and identifying chikungunya virus-specific responses RT-PCR using nested primer pairs is used to amplify several chikungunya-specific genes from whole blood, generating thousands to millions of copies of the genes in order to identify them RT-PCR can also be used to quantify the viral load in the blood Using RT-PCR, diagnostic results can be available in one to two days56 Serological diagnosis requires a larger amount of blood than the other methods, and uses an ELISA assay to measure chikungunya-specific IgM levels in the blood serum One advantage offered by serological diagnosis is that serum IgM is detectable from 5 days to months after the onset of symptoms, but drawbacks are that results may require two to three days, and false positives can occur with infection due to other related viruses, such as o'nyong'nyong virus and Semliki Forest virus56

Presently, there is no specific way to test for chronic signs and symptoms associated with Chikungunya fever although nonspecific laboratory findings such as C reactive protein and elevated cytokines can correlate with disease activity57


A aegypti mosquito biting a person

Because no approved vaccine exists, the most effective means of prevention are protection against contact with the disease-carrying mosquitoes and controlling mosquito populations by limiting their habitat4 Mosquito control focuses on eliminating the standing water where mosquitos lay eggs and develop as larva; if elimination of the standing water is not possible, insecticides or biological control agents can be added11 Methods of protection against contact with mosquitos include using insect repellents with substances such as DEET, icaridin, PMD p-menthane-3,8-diol, a substance derived from the lemon eucalyptus tree, or IR3535 However, increasing insecticide resistance presents a challenge to chemical control methods

Wearing bite-proof long sleeves and trousers also offers protection, and garments can be treated with pyrethroids, a class of insecticides that often has repellent properties Vaporized pyrethroids for example in mosquito coils are also insect repellents As infected mosquitos often feed and rest inside homes, securing screens on windows and doors will help to keep mosquitoes out of the house In the case of the day-active A aegypti and A albopictus, however, this will have only a limited effect, since many contacts between the mosquitoes and humans occur outdoors


As of 2017update, no approved vaccines are available A phase-II vaccine trial used a live, attenuated virus, to develop viral resistance in 98% of those tested after 28 days and 85% still showed resistance after one year58 However, 8% of people reported transient joint pain, and attenuation was found to be due to only two mutations in the E2 glycoprotein59 Alternative vaccine strategies have been developed, and show efficacy in mouse models6061 In August 2014 researchers at the National Institute of Allergy and Infectious Diseases in the USA were testing an experimental vaccine which uses virus-like particles VLPs instead of attenuated virus All the 25 people participated in this phase 1 trial developed strong immune responses62 Phase 2 trial will commence using 400 adults aged 18 to 60 and take place at 6 locations in the Caribbean63 Even with a vaccine, mosquito population control and bite prevention will be necessary to control chikungunya disease64


Currently, no specific treatment for chikungunya is available4 Supportive care is recommended, and symptomatic treatment of fever and joint swelling includes the use of nonsteroidal anti-inflammatory drugs such as naproxen, non-aspirin analgesics such as paracetamol acetaminophen and fluids4 Aspirin is not recommended due to the increased risk of bleeding65 Despite anti-inflammatory effects, corticosteroids are not recommended during the acute phase of disease, as they may cause immunosuppression and worsen infection10

Passive immunotherapy has potential benefit in treatment of chikungunya Studies in animals using passive immunotherapy have been effective, and clinical studies using passive immunotherapy in those particularly vulnerable to severe infection are currently in progress66 Passive immunotherapy involves administration of anti-CHIKV hyperimmune human intravenous antibodies immunoglobulins to those exposed to a high risk of chikungunya infection No antiviral treatment for chikungunya virus is currently available, though testing has shown several medications to be effective in vitro8

Chronic arthritisedit

In those who have more than two weeks of arthritis, ribavirin may be useful4 The effect of chloroquine is not clear4 It does not appear to help acute disease, but tentative evidence indicates it might help those with chronic arthritis4 Steroids do not appear to be an effective treatment4 NSAIDs and simple analgesics can be used to provide partial symptom relief in most cases Methotrexate, a drug used in the treatment of rheumatoid arthritis, has been shown to have benefit in treating inflammatory polyarthritis resulting from chikungunya, though the drug mechanism for improving viral arthritis is unclear18


The mortality rate of chikungunya is slightly less than 1 in 100067 Those over the age of 65, neonates, and those with underlying chronic medical problems are most likely to have severe complications37 Neonates are vulnerable as it is possible to vertically transmit chikungunya from mother to infant during delivery, which results in high rates of morbidity, as infants lack fully developed immune systems37 The likelihood of prolonged symptoms or chronic joint pain is increased with increased age and prior rheumatological disease2122


Main article: Epidemiology of chikungunya Dark green denotes countries with current or previous local transmission of CHIKV, per CDC as of July 2015 A albopictus distribution as of December 2007
Dark blue: Native range
Teal: introduced

Historically, chikungunya has been present mostly in the developing world The disease causes an estimated 3 million infections each year68 Epidemics in the Indian Ocean, Pacific Islands, and in the Americas, continue to change the distribution of the disease69 In Africa, chikungunya is spread by a sylvatic cycle in which the virus largely cycles between other non-human primates, small mammals, and mosquitos between human outbreaks9 During outbreaks, due to the high concentration of virus in the blood of those in the acute phase of infection, the virus can circulate from humans to mosquitoes and back to humans9 The transmission of the pathogen between humans and mosquitoes that exist in urban environments was established on multiple occasions from strains occurring on the eastern half of Africa in non-human primate hosts11 This emergence and spread beyond Africa may have started as early as the 18th century11 Currently, available data does not indicate whether the introduction of chikungunya into Asia occurred in the 19th century or more recently, but this epidemic Asian strain causes outbreaks in India and continues to circulate in Southeast Asia11 In Africa, outbreaks were typically tied to heavy rainfall causing increased mosquito population In recent outbreaks in urban centers, the virus has spread by circulating between humans and mosquitoes10

Global rates of chikungunya infection are variable, depending on outbreaks When chikungunya was first identified in 1952, it had a low-level circulation in West Africa, with infection rates linked to rainfall Beginning in the 1960s, periodic outbreaks were documented in Asia and Africa However, since 2005, following several decades of relative inactivity, chikungunya has re-emerged and caused large outbreaks in Africa, Asia, and the Americas In India, for instance, chikungunya re-appeared following 32 years of absence of viral activity70 Outbreaks have occurred in Europe, the Caribbean, and South America, areas in which chikungunya was not previously transmitted Local transmission has also occurred in the United States and Australia, countries in which the virus was previously unknown10 In 2005, an outbreak on the island of Réunion was the largest then documented, with an estimated 266,000 cases on an island with a population of approximately 770,00071 In a 2006 outbreak, India reported 125 million suspected cases72 Chikungunya was recently introduced to the Americas, and from 2013-14 in the Americas, 1,118,763 suspected cases and 24,682 confirmed cases were reported by the PAHO73

An analysis of the chikungunya virus's genetic code suggests that the increased severity of the 2005–present outbreak may be due to a change in the genetic sequence which altered the E1 segment of the virus' viral coat protein, a variant called E1-A226V This mutation potentially allows the virus to multiply more easily in mosquito cells74 The change allows the virus to use the Asian tiger mosquito an invasive species as a vector in addition to the more strictly tropical main vector, Aedes aegypti75 Enhanced transmission of chikungunya virus by A albopictus could mean an increased risk for outbreaks in other areas where the Asian tiger mosquito is present76 A albopictus is an invasive species which has spread through Europe, the Americas, the Caribbean, Africa and the Middle East

After the detection of zika virus in Brazil in April 2015, the first ever in the Western Hemisphere,7778 it is now thought some chikungunya and dengue cases could in fact be zika virus cases or coinfections


The word 'chikungunya' is believed to have been derived from a description in the Makonde language, meaning "that which bends up", of the contorted posture of people affected with the severe joint pain and arthritic symptoms associated with this disease79 The disease was first described by Marion Robinson80 and WHR Lumsden81 in 1955, following an outbreak in 1952 on the Makonde Plateau, along the border between Mozambique and Tanganyika the mainland part of modern-day Tanzania

According to the initial 1955 report about the epidemiology of the disease, the term 'chikungunya' is derived from the Makonde root verb kungunyala, meaning to dry up or become contorted In concurrent research, Robinson glossed the Makonde term more specifically as "that which bends up" Subsequent authors apparently overlooked the references to the Makonde language and assumed the term to have been derived from Swahili, the lingua franca of the region The erroneous attribution to Swahili has been repeated in numerous print sources82 Many erroneous spellings of the name of the disease are also in common use

Since its discovery in Tanganyika, Africa, in 1952, chikungunya virus outbreaks have occurred occasionally in Africa, South Asia, and Southeast Asia, but recent outbreaks have spread the disease over a wider range

The first recorded outbreak of this disease may have been in 177983 This is in agreement with the molecular genetics evidence that suggests it evolved around the year 170084

Biological weaponedit

Chikungunya was one of more than a dozen agents researched as potential biological weapons85


Infection was reduced in mosquitoes with the wMel strain of Wolbachia8687

It is part of the group of neglected tropical diseases88


  1. ^ "chikungunya" Oxford Learner's Dictionary Oxford University Press Retrieved 4 November 2014 
  2. ^ a b c d e f g h i "Chikungunya Virus Symptoms, Diagnosis, & Treatment" CDC 6 April 2016 Retrieved 26 September 2016 
  3. ^ a b c d e f g h i j k l m n o "Chikungunya Fact sheet" WHO April 2016 Retrieved 26 September 2016 
  4. ^ a b c d e f g h i j k l Caglioti, C; Lalle, E; Castilletti, C; Carletti, F; Capobianchi, MR; Bordi, L July 2013 "Chikungunya virus infection: an overview" The new microbiologica 36 3: 211–27 PMID 23912863 
  5. ^ "Prevention" CDC 26 February 2016 Retrieved 26 September 2016 
  6. ^ Staples JE, Fischer M 2014 "Chikungunya virus in the Americas--what a vectorborne pathogen can do" N Engl J Med 371 10: 887–9 PMC 4624217  PMID 25184860 doi:101056/NEJMp1407698 
  7. ^ "2016 provisional data for the United States" CDC 20 September 2016 Retrieved 26 September 2016 
  8. ^ a b c d e f g h i Thiberville, Simon-Djamel; Moyen, Nanikaly; Dupuis-Maguiraga, Laurence; Nougairede, Antoine; Gould, Ernest A; Roques, Pierre; de Lamballerie, Xavier 2013 "Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy" Antiviral Research 99 3: 345–370 ISSN 0166-3542 doi:101016/jantiviral201306009 
  9. ^ a b c d e Powers AM, Logue CH September 2007 "Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus" J Gen Virol 88 Pt 9: 2363–77 PMID 17698645 doi:101099/vir082858-0 
  10. ^ a b c d e f g h i Burt, Felicity J; Rolph, Micheal S; Rulli, Nestor E; Mahalingam, Suresh; Heise, Mark T 2012 "Chikungunya: a re-emerging virus" The Lancet 379 9816: 662–671 ISSN 0140-6736 PMID 22100854 doi:101016/S0140-67361160281-X 
  11. ^ a b c d e f g h i Weaver, Scott C; Lecuit, Marc 2015 "Chikungunya Virus and the Global Spread of a Mosquito-Borne Disease" New England Journal of Medicine 372 13: 1231–1239 ISSN 0028-4793 PMID 25806915 doi:101056/NEJMra1406035 
  12. ^ Chhabra M, Mittal V, Bhattacharya D, Rana U, Lal S 2008 "Chikungunya fever: a re-emerging viral infection" Indian J Med Microbiol 26 1: 5–12 PMID 18227590 doi:104103/0255-085738850 
  13. ^ Capeding, MR; Chua, MN; Hadinegoro, SR; Hussain, II; Nallusamy, R; Pitisuttithum, P; Rusmil, K; Thisyakorn, U; Thomas, SJ; Huu Tran, N; Wirawan, DN; Yoon, IK; Bouckenooghe, A; Hutagalung, Y; Laot, T; Wartel, TA 2013 "Dengue and other common causes of acute febrile illness in Asia: an active surveillance study in children" PLoS neglected tropical diseases 7 7: e2331 PMC 3723539  PMID 23936565 doi:101371/journalpntd0002331 
  14. ^ Powers, Ann "Chikungunya" CDC Retrieved 12 May 2014 
  15. ^ Mahendradas P, Ranganna SK, Shetty R, Balu R, Narayana KM, Babu RB, Shetty BK February 2008 "Ocular manifestations associated with chikungunya" Ophthalmology 115 2: 287–91 PMID 17631967 doi:101016/jophtha200703085 
  16. ^ Simon, Fabrice; Javelle, Emilie; Oliver, Manuela; Leparc-Goffart, Isabelle; Marimoutou, Catherine 6 April 2011 "Chikungunya Virus Infection" Current Infectious Disease Reports 13 3: 218–228 doi:101007/s11908-011-0180-1 
  17. ^ MacFadden, D R; Bogoch, I I 2014 "Chikungunya" Canadian Medical Association Journal 186 10: 775–775 ISSN 0820-3946 doi:101503/cmaj140031 
  18. ^ a b Parashar, Deepti; Cherian, Sarah 2014 "Antiviral Perspectives for Chikungunya Virus" BioMed Research International 2014: 1–11 ISSN 2314-6133 doi:101155/2014/631642 
  19. ^ Munoz-Zanzi, Claudia; Javelle, Emilie; Ribera, Anne; Degasne, Isabelle; Gaüzère, Bernard-Alex; Marimoutou, Catherine; Simon, Fabrice 2015 "Specific Management of Post-Chikungunya Rheumatic Disorders: A Retrospective Study of 159 Cases in Reunion Island from 2006-2012" PLOS Neglected Tropical Diseases 9 3: e0003603 ISSN 1935-2735 doi:101371/journalpntd0003603 
  20. ^ Fourie ED, Morrison JG 28 July 1979 "Rheumatoid arthritic syndrome after chikungunya fever" South African medical Suid-Afrikaanse tydskrif vir geneeskunde 56 4: 130–2 PMID 494034 
  21. ^ a b c d Schilte C, Staikowsky F, Staikovsky F, Couderc T, Madec Y, Carpentier F, Kassab S, Albert ML, Lecuit M, Michault A 2013 "Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study" PLoS neglected tropical diseases 7 3: e2137 PMC 3605278  PMID 23556021 doi:101371/journalpntd0002137 
  22. ^ a b c Gérardin P, Fianu A, Michault A, Mussard C, Boussaïd K, Rollot O, Grivard P, Kassab S, Bouquillard E, Borgherini G, Gaüzère BA, Malvy D, Bréart G, Favier F 9 January 2013 "Predictors of Chikungunya rheumatism: a prognostic survey ancillary to the TELECHIK cohort study" Arthritis Research & Therapy 15 1: R9 PMC 3672753  PMID 23302155 doi:101186/ar4137 
  23. ^ a b Moro ML, Grilli E, Corvetta A, Silvi G, Angelini R, Mascella F, Miserocchi F, Sambo P, Finarelli AC, Sambri V, Gagliotti C, Massimiliani E, Mattivi A, Pierro AM, Macini P August 2012 "Long-term chikungunya infection clinical manifestations after an outbreak in Italy: a prognostic cohort study" The Journal of infection 65 2: 165–72 PMID 22522292 doi:101016/jjinf201204005 
  24. ^ Sissoko D, Malvy D, Ezzedine K, Renault P, Moscetti F, Ledrans M, Pierre V 2009 "Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period" PLoS neglected tropical diseases 3 3: e389 PMC 2647734  PMID 19274071 doi:101371/journalpntd0000389 
  25. ^ Larrieu S, Pouderoux N, Pistone T, Filleul L, Receveur MC, Sissoko D, Ezzedine K, Malvy D Jan 2010 "Factors associated with persistence of arthralgia among Chikungunya virus-infected travellers: report of 42 French cases" Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 47 1: 85–8 PMID 20004145 doi:101016/jjcv200911014 
  26. ^ Manimunda SP, Vijayachari P, Uppoor R, Sugunan AP, Singh SS, Rai SK, Sudeep AB, Muruganandam N, Chaitanya IK, Guruprasad DR June 2010 "Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging" Transactions of the Royal Society of Tropical Medicine and Hygiene 104 6: 392–9 PMID 20171708 doi:101016/jtrstmh201001011 
  27. ^ a b Ozden S, Huerre M, Riviere JP, Coffey LL, Afonso PV, Mouly V, de Monredon J, Roger JC, El Amrani M, Yvin JL, Jaffar MC, Frenkiel MP, Sourisseau M, Schwartz O, Butler-Browne G, Desprès P, Gessain A, Ceccaldi PE 13 June 2007 "Human muscle satellite cells as targets of Chikungunya virus infection" PLoS ONE 2 6: e527 PMC 1885285  PMID 17565380 doi:101371/journalpone0000527 
  28. ^ Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, Das T, Li-Pat-Yuen G, Dassa B, Denizot M, Guichard E, Ribera A, Henni T, Tallet F, Moiton MP, Gauzère BA, Bruniquet S, Jaffar Bandjee Z, Morbidelli P, Martigny G, Jolivet M, Gay F, Grandadam M, Tolou H, Vieillard V, Debré P, Autran B, Gasque P 15 May 2010 "Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response" Journal of immunology Baltimore, Md : 1950 184 10: 5914–27 PMID 20404278 doi:104049/jimmunol0900255 
  29. ^ Hawman DW, Stoermer KA, Montgomery SA, Pal P, Oko L, Diamond MS, Morrison TE Dec 2013 "Chronic joint disease caused by persistent chikungunya virus infection is controlled by the adaptive immune response" Journal of Virology 87 24: 13878–88 PMC 3838294  PMID 24131709 doi:101128/JVI02666-13 
  30. ^ Teo TH, Lum FM, Claser C, Lulla V, Lulla A, Merits A, Rénia L, Ng LF 1 January 2013 "A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice" Journal of immunology Baltimore, Md : 1950 190 1: 259–69 PMID 23209328 doi:104049/jimmunol1202177 
  31. ^ Labadie K, Larcher T, Joubert C, Mannioui A, Delache B, Brochard P, Guigand L, Dubreil L, Lebon P, Verrier B, de Lamballerie X, Suhrbier A, Cherel Y, Le Grand R, Roques P March 2010 "Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages" The Journal of Clinical Investigation 120 3: 894–906 PMC 2827953  PMID 20179353 doi:101172/JCI40104 
  32. ^ Sun, S; Xiang, Y; Akahata, W; Holdaway, H; Pal, P; Zhang, X; Diamond, M S; Nabel, G J; Rossmann, M G 2013 "Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization" ELife 2: e00435 PMC 3614025  PMID 23577234 doi:107554/eLife00435 
  33. ^ a b Weaver, Scott C; Osorio, Jorge E; Livengood, Jill A; Chen, Rubing; Stinchcomb, Dan T 2012 "Chikungunya virus and prospects for a vaccine" Expert Review of Vaccines 11 9: 1087–1101 ISSN 1476-0584 doi:101586/erv1284 
  34. ^ Powers AM, Brault AC, Shirako Y, Strauss EG, Kang W, Strauss JH, Weaver SC November 2001 "Evolutionary relationships and systematics of the alphaviruses" Journal of Virology 75 21: 10118–31 PMC 114586  PMID 11581380 doi:101128/JVI752110118-101312001 
  35. ^ "NIAID Category A, B, and C Priority Pathogens" Retrieved 1 January 2014 
  36. ^ "Biosafety in Microbiological and Biomedical Laboratories BMBL Fifth Edition" PDF Retrieved 1 January 2014 
  37. ^ a b c d Morrison, T E 2014 "Reemergence of Chikungunya Virus" Journal of Virology 88 20: 11644–11647 ISSN 0022-538X doi:101128/JVI01432-14 
  38. ^ Ng LC, Hapuarachchi HC 2010 "Tracing the path of Chikungunya virus--evolution and adaptation" Infect Genet Evol 10 7: 876–85 PMID 20654736 doi:101016/jmeegid201007012 
  39. ^ Powers AM, Brault AC, Tesh RB, Weaver SC February 2000 "Re-emergence of Chikungunya and O'nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships" J Gen Virol 81 Pt 2: 471–9 
  40. ^ Sahadeo NSD, Allicock OM, De Salazar PM, Auguste AJ, Widen S, Olowokure B, Gutierrez C, Valadere AM, Polson-Edwards K, Weaver SC, Carrington CVF 2017 Understanding the evolution and spread of chikungunya virus in the Americas using complete genome sequences Virus Evol 31:vex010 doi:101093/ve/vex010 eCollection
  41. ^ Enserink M 2007 "EPIDEMIOLOGY: Tropical Disease Follows Mosquitoes to Europe" Science 317 5844: 1485 PMID 17872417 doi:101126/science31758441485a 
  42. ^ Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, Rudnicka D, Sol-Foulon N, Le Roux K, Prevost MC, Fsihi H, Frenkiel MP, Blanchet F, Afonso PV, Ceccaldi PE, Ozden S, Gessain A, Schuffenecker I, Verhasselt B, Zamborlini A, Saïb A, Rey FA, Arenzana-Seisdedos F, Desprès P, Michault A, Albert ML, Schwartz O June 2007 "Characterization of reemerging chikungunya virus" PLoS Pathogens 3 6: e89 PMC 1904475  PMID 17604450 doi:101371/journalppat0030089 
  43. ^ Schilte C, Couderc T, Chretien F, Sourisseau M, Gangneux N, Guivel-Benhassine F, Kraxner A, Tschopp J, Higgs S, Michault A, Arenzana-Seisdedos F, Colonna M, Peduto L, Schwartz O, Lecuit M, Albert ML 15 February 2010 "Type I IFN controls chikungunya virus via its action on nonhematopoietic cells" The Journal of Experimental Medicine 207 2: 429–42 PMC 2822618  PMID 20123960 doi:101084/jem20090851 
  44. ^ Rohatgi A, Corbo JC, Monte K, Higgs S, Vanlandingham DL, Kardon G, Lenschow DJ 11 December 2013 "Infection of myofibers contributes to the increased pathogenicity during infection with an epidemic strain of Chikungunya Virus" Journal of Virology 88 5: 2414–25 PMC 3958092  PMID 24335291 doi:101128/JVI02716-13 
  45. ^ a b Schilte C, Couderc T, Chretien F, Sourisseau M, Gangneux N, Guivel-Benhassine F, Kraxner A, Tschopp J, Higgs S, Michault A, Arenzana-Seisdedos F, Colonna M, Peduto L, Schwartz O, Lecuit M, Albert ML February 2010 "Type I IFN controls chikungunya virus via its action on nonhematopoietic cells" J Exp Med 207 2: 429–42 PMC 2822618  PMID 20123960 doi:101084/jem20090851 
  46. ^ Couderc T, Chrétien F, Schilte C, Disson O, Brigitte M, Guivel-Benhassine F, Touret Y, Barau G, Cayet N, Schuffenecker I, Desprès P, Arenzana-Seisdedos F, Michault A, Albert ML, Lecuit M February 2008 "A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease" PLoS Pathog 4 2: e29 PMC 2242832  PMID 18282093 doi:101371/journalppat0040029 
  47. ^ Partidos CD, Weger J, Brewoo J, Seymour R, Borland EM, Ledermann JP, Powers AM, Weaver SC, Stinchcomb DT, Osorio JE April 2011 "Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon IFN signaling" Vaccine 29 16: 3067–73 PMC 3081687  PMID 21300099 doi:101016/jvaccine201101076 
  48. ^ a b White LK, Sali T, Alvarado D, Gatti E, Pierre P, Streblow D, Defilippis VR January 2011 "Chikungunya virus induces IPS-1-dependent innate immune activation and protein kinase R-independent translational shutoff" J Virol 85 1: 606–20 PMC 3014158  PMID 20962078 doi:101128/JVI00767-10 
  49. ^ Rudd PA, Wilson J, Gardner J, Larcher T, Babarit C, Le TT, Anraku I, Kumagai Y, Loo YM, Gale M, Akira S, Khromykh AA, Suhrbier A September 2012 "Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock" J Virol 86 18: 9888–98 PMC 3446587  PMID 22761364 doi:101128/JVI00956-12 
  50. ^ Schilte C, Buckwalter MR, Laird ME, Diamond MS, Schwartz O, Albert ML April 2012 "Cutting edge: independent roles for IRF-3 and IRF-7 in hematopoietic and nonhematopoietic cells during host response to Chikungunya infection" J Immunol 188 7: 2967–71 PMID 22371392 doi:104049/jimmunol1103185 
  51. ^ Akhrymuk I, Kulemzin SV, Frolova EI July 2012 "Evasion of the innate immune response: the Old World alphavirus nsP2 protein induces rapid degradation of Rpb1, a catalytic subunit of RNA polymerase II" J Virol 86 13: 7180–91 PMC 3416352  PMID 22514352 doi:101128/JVI00541-12 
  52. ^ Fros JJ, Liu WJ, Prow NA, Geertsema C, Ligtenberg M, Vanlandingham DL, Schnettler E, Vlak JM, Suhrbier A, Khromykh AA, Pijlman GP October 2010 "Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling" J Virol 84 20: 10877–87 PMC 2950581  PMID 20686047 doi:101128/JVI00949-10 
  53. ^ Voss, JE; Vaney, MC; Duquerroy, S; Vonrhein, C; Girard-Blanc, C; Crublet, E; Thompson, A; Bricogne, G; Rey, FA 2 December 2010 "Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography" Nature 468 7324: 709–12 PMID 21124458 doi:101038/nature09555 
  54. ^ "Chikungunya Virus Infections" New England Journal of Medicine 373: 93–95 doi:101056/NEJMc1505501 
  55. ^ Morens DM and Fauci AS 4 September 2014 "Chikungunya at the Door—Déjà Vu All Over Again" New England Journal of Medicine 371 10: 885–887 PMID 25029435 doi:101056/NEJMp1408509 Retrieved 12 September 2014 
  56. ^ a b c "Laboratory Diagnosis of Chikungunya Fevers" World Health Organization Archived from the original on 8 September 2012 Retrieved 20 May 2013 
  57. ^ Schilte, C; Staikowsky, F; Couderc, T; Madec, Y; Carpentier, F; Kassab, S; Albert, ML; Lecuit, M; Michault, A 2013 "Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study" PLoS neglected tropical diseases 7 3: e2137 PMC 3605278  PMID 23556021 doi:101371/journalpntd0002137 
  58. ^ Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA June 2000 "Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218" Am J Trop Med Hyg 62 6: 681–5 PMID 11304054 
  59. ^ Gorchakov R, Wang E, Leal G, Forrester NL, Plante K, Rossi SL, Partidos CD, Adams AP, Seymour RL, Weger J, Borland EM, Sherman MB, Powers AM, Osorio JE, Weaver SC June 2012 "Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein" Journal of Virology 86 11: 6084–96 PMC 3372191  PMID 22457519 doi:101128/JVI06449-11 
  60. ^ Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, Tsetsarkin K, Borland EM, Powers AM, Seymour R, Stinchcomb DT, Osorio JE, Frolov I, Weaver SC Jul 2011 "Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism" PLoS Pathogens 7 7: e1002142 PMC 3145802  PMID 21829348 doi:101371/journalppat1002142 
  61. ^ Hallengärd D, Kakoulidou M, Lulla A, Kümmerer BM, Johansson DX, Mutso M, Lulla V, Fazakerley JK, Roques P, Le Grand R, Merits A, Liljeström P 26 December 2013 "Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice" Journal of Virology 88 5: 2858–66 PMC 3958085  PMID 24371047 doi:101128/JVI03453-13 
  62. ^ "Experimental chikungunya vaccine passes first test" NPR 15 August 2014 Retrieved 15 August 2014 
  63. ^ Al Idrus, Amirah 2 December 2015 "NIAID to bring Chikungunya vaccine into Phase II" fiercevaccinescom Retrieved 24 March 2016 
  64. ^ Morens DM, Fauci AS 4 September 2014 "Chikungunya at the door--déjà vu all over again" The New England Journal of Medicine 371 10: 885–7 PMID 25029435 doi:101056/nejmp1408509 
  65. ^ "Chikungunya—Fact sheet" European Centre for Disease Prevention and Control ECDC Retrieved 2013-12-17 
  66. ^ Couderc, T; Khandoudi, N; Grandadam, M; Visse, C; Gangneux, N; Bagot, S; Prost, JF; Lecuit, M 15 August 2009 "Prophylaxis and therapy for Chikungunya virus infection" The Journal of Infectious Diseases 200 4: 516–23 PMID 19572805 doi:101086/600381 
  67. ^ Mavalankar D, Shastri P, Bandyopadhyay T, Parmar J, Ramani KV 2008 "Increased Mortality Rate Associated with Chikungunya Epidemic, Ahmedabad, India" Emerging Infectious Diseases 14 3: 412–5 PMC 2570824  PMID 18325255 doi:103201/eid1403070720 
  68. ^ Seppa, Nathan 2 Jun 2015 "Chikungunya is on the move" Science News Retrieved 13 June 2015 
  69. ^ Poh, Lisa Ng Fong; Sam, I-Ching; Loong, Shih-Keng; Michael, Jasmine Chandramathi; Chua, Chong-Long; Wan Sulaiman, Wan Yusoff; Vythilingam, Indra; Chan, Shie-Yien; Chiam, Chun-Wei; Yeong, Yze-Shiuan; AbuBakar, Sazaly; Chan, Yoke-Fun 2012 "Genotypic and Phenotypic Characterization of Chikungunya Virus of Different Genotypes from Malaysia" PLoS ONE 7 11: e50476 ISSN 1932-6203 PMC 3507689  PMID 23209750 doi:101371/journalpone0050476 
  70. ^ Lahariya C, Pradhan SK December 2006 "Emergence of chikungunya virus in Indian subcontinent after 32 years: A review" PDF J Vector Borne Dis 43 4: 151–60 PMID 17175699 
  71. ^ Roth, Adam; Hoy, Damian; Horwood, Paul F; Ropa, Berry; Hancock, Thane; Guillaumot, Laurent; Rickart, Keith; Frison, Pascal; Pavlin, Boris; Souares, Yvan 2014 "Preparedness for Threat of Chikungunya in the Pacific" Emerging Infectious Diseases 20 8 ISSN 1080-6040 PMC 4111160  PMID 25062306 doi:103201/eid2008130696 
  72. ^ Muniaraj M 2014 "Fading chikungunya fever from India: beginning of the end of another episode" Indian J Med Res 139 3: 468–70 PMC 4069744  PMID 24820844 
  73. ^ "Number of cumulative cases 2013-2014" http://wwwpahoorg Pan-American Health Organization PAHO 15 May 2015 Retrieved 19 July 2015  External link in |website= help
  74. ^ Schuffenecker I, Iteman I, Michault A, et al July 2006 "Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak" PLoS Med 3 7: e263 PMC 1463904  PMID 16700631 doi:101371/journalpmed0030263 
  75. ^ Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S 2007 "A Single Mutation in Chikungunya Virus Affects Vector Specificity and Epidemic Potential" PLoS Pathog 3 12: e201 PMC 2134949  PMID 18069894 doi:101371/journalppat0030201 
  76. ^ Liumbruno GM, Calteri D, Petropulacos K, et al 2008 "The Chikungunya epidemic in Italy and its repercussion on the blood system" Blood Transfusion = Trasfusione Del Sangue 6 4: 199–210 PMC 2626913  PMID 19112735 doi:102450/20080016-08 inactive 2017-01-31 
  77. ^ http://g1globocom/bahia/noticia/2015/04/identificado-virus-causador-de-doenca-misteriosa-em-salvador-e-rmshtml
  78. ^ http://wwwcenariomtcombr/noticia/442333/sao-paulo-ja-pode-ter-casos-de-zika-virushtml
  79. ^ Centers for Disease Control Prevention CDC 29 September 2006 "Chikungunya fever diagnosed among international travelers—United States, 2005–2006" MMWR Morb Mortal Wkly Rep 55 38: 1040–2 PMID 17008866 
  80. ^ Robinson MC 1955 "An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53 I Clinical features" Trans R Soc Trop Med Hyg 49 1: 28–32 PMID 14373834 doi:101016/0035-92035590080-8 
  81. ^ Lumsden WH 1955 "An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952–53 II General description and epidemiology" Trans R Soc Trop Med Hyg 49 1: 33–57 PMID 14373835 doi:101016/0035-92035590081-X 
  82. ^ Benjamin M 2008 "Chikungunya is NOT a Swahili word, it is from the Makonde language!" 
  83. ^ Carey DE July 1971 "Chikungunya and dengue: a case of mistaken identity" J Hist Med Allied Sci 26 3: 243–62 PMID 4938938 doi:101093/jhmas/XXVI3243 
  84. ^ Cherian SS, Walimbe AM, Jadhav SM, Gandhe SS, Hundekar SL, Mishra AC, Arankalle VA January 2009 "Evolutionary rates and timescale comparison of Chikungunya viruses inferred from the whole genome/E1 gene with special reference to the 2005-07 outbreak in the Indian subcontinent" Infect Genet Evol 9 1: 16–23 PMID 18940268 doi:101016/jmeegid200809004 
  85. ^ "Chemical and Biological Weapons: Possession and Programs Past and Present", James Martin Center for Nonproliferation Studies, Middlebury College, 9 April 2002, accessed 18 June 2014
  86. ^ http://journalsplosorg/plosntds/articleid=101371/journalpntd0001892 Impact of Wolbachia on Infection with Chikungunya and Yellow Fever Viruses in the Mosquito Vector Aedes aegypti
  87. ^ http://journalsplosorg/plosntds/articleid=101371/journalpntd0004677 The wMel Strain of Wolbachia Reduces Transmission of Chikungunya Virus in Aedes aegypti
  88. ^ "Neglected tropical diseases" WHO Retrieved 26 September 2016 

External linksedit

  • ICD-10: A920
  • ICD-9-CM: 0654, 0663
  • MeSH: D018354
  • DiseasesDB: 32213
External resources
  • eMedicine: article/2225687
  • Orphanet: 324625

  • Viruses portal
  • Chikungunya fact sheet—from WHO World Health Organization
  • Chikungunya outbreaks—from WHO World Health Organization
  • Togaviridae—from ViPR Virus Pathogen Resource
  • "Chikungunya" European Centre for Disease Prevention and Control 23 January 2008 Retrieved 20 May 2013 
  • Chikungunya in Cuba
  • Chikungunya: The key role of “innate immunity”

chikungunya, chikungunya mosquito, chikungunya pronunciation, chikungunya sintomas, chikungunya symptoms, chikungunya treatment, chikungunya vaccine, chikungunya virus, chikungunya virus rash pictures, chikungunya virus symptoms and signs

Chikungunya Information about


  • user icon

    Chikungunya beatiful post thanks!


Chikungunya viewing the topic.
Chikungunya what, Chikungunya who, Chikungunya explanation

There are excerpts from wikipedia on this article and video

Random Posts

IP address blocking

IP address blocking

IP address blocking prevents connection between a server or website and certain IP addresses or rang...
Gisele Bündchen

Gisele Bündchen

Gisele Caroline Bündchen1 Portuguese pronunciation: ʒiˈzɛli kaɾoˈlini ˈbĩtʃẽj, German pronuncia...
Sheldon, West Midlands

Sheldon, West Midlands

Sheldon is an area of east Birmingham, England Historically part of Warwickshire, it is close to the...
Beverly, Chicago

Beverly, Chicago

Beverly is one of the 77 community areas of Chicago, Illinois It is located on the South Side on the...